Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Update

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 226,620 shares, a growth of 62.8% from the August 31st total of 139,192 shares. Approximately 1.4% of the company’s shares are sold short. Based on an average daily trading volume, of 67,897 shares, the short-interest ratio is presently 3.3 days.

Institutional Investors Weigh In On Marker Therapeutics

A hedge fund recently raised its position in Marker Therapeutics stock. Renaissance Technologies LLC increased its holdings in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 41.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 175,294 shares of the company’s stock after purchasing an additional 51,644 shares during the period. Renaissance Technologies LLC owned 1.05% of Marker Therapeutics worth $228,000 as of its most recent filing with the Securities and Exchange Commission. 22.39% of the stock is currently owned by institutional investors and hedge funds.

Marker Therapeutics Price Performance

NASDAQ MRKR traded down $0.02 during trading hours on Thursday, reaching $1.05. The company’s stock had a trading volume of 127,493 shares, compared to its average volume of 149,741. The stock has a market cap of $17.50 million, a P/E ratio of -2.56 and a beta of 1.53. The firm has a fifty day simple moving average of $1.21 and a 200-day simple moving average of $1.35. Marker Therapeutics has a 52 week low of $0.84 and a 52 week high of $2.46.

Marker Therapeutics (NASDAQ:MRKR) last released its earnings results on Friday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.16. Marker Therapeutics had a negative return on equity of 56.96% and a negative net margin of 343.03%. On average, research analysts expect that Marker Therapeutics will post -0.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MRKR has been the topic of a number of research reports. HC Wainwright restated a “buy” rating on shares of Marker Therapeutics in a report on Friday, August 21st. Weiss Ratings upgraded Marker Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 18th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Marker Therapeutics has a consensus rating of “Hold” and an average price target of $10.00.

About Marker Therapeutics

Marker Therapeutics, Inc (NASDAQ: MRKR) is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s approach uses multiTAA-specific T cells, which are designed to recognize and attack multiple tumor-associated antigens rather than a single target. Marker Therapeutics is developing these therapies for patients with solid tumors and certain hematologic malignancies.

The company’s lead investigational product, MT-601, is an autologous multiTAA-specific T-cell therapy being evaluated in clinical development, including for pancreatic cancer.